Equities

Grand Pharmaceutical Group Ltd

Grand Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.72
  • Today's Change0.01 / 0.21%
  • Shares traded1.95m
  • 1 Year change+4.89%
  • Beta0.6691
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in HKD

The 2 analysts offering 12 month price targets for Grand Pharmaceutical Group Ltd have a median target of 5.80, with a high estimate of 6.20 and a low estimate of 5.40. The median estimate represents a 22.88% increase from the last price of 4.72.
High31.4%6.20
Med22.9%5.80
Low14.4%5.40

Dividends

In 2023, Grand Pharmaceutical Group Ltd reported a dividend of 0.26 HKD, which represents a 85.71% increase over last year. The 2 analysts covering the company expect dividends of 0.26 HKD for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)85.71%
More ▼

Earnings history & estimates in HKD

Grand Pharmaceutical Group Ltd reported annual 2023 earnings of 0.536 per share on Mar 19, 2024.
Average growth rate+14.09%
More ▼

Revenue history & estimates in HKD

China Grand Pharmaceutical and Healthcare Holdings Limited had revenues for the full year 2023 of 10.53bn. This was 10.12% above the prior year's results.
Average growth rate+13.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.